This decrease was partially offset by the receipt of $8.7 million from sales of common stock under the Cantor agreement. At June 30, 2017, Celldex had 127.4 million shares outstanding. Revenues: Total revenue was $3.8 million in the …
In connection with the CuraGen Merger, Celldex (i) issued 0.2739 shares of Celldex in exchange for each share of …
Last week Healthcor disclosed a 5.86% stake in Celldex (CLDX) in a 13G filing. They paid around $3.30 per share on May 18th when the stock closed at $3.31. The stock currently trades at $3.70, giving Healthcor a 10+% return in less than …
... Therapeutics Inc. (CLDX) is a biotechnology company focused on developing antibody-based combination immunotherapies for the treatment of cancer and other difficult-to-treat diseases. RTTNews had alerted readers to the …
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the completed merger of Callisto Merger Corporation, its wholly-owned subsidiary, with and into Celldex Therapeutics, …
However, analysts have a completely different take on the shares. All eight brokerage firms with coverage on the stock rate it a "strong buy." It's rare to see Celldex Therapeutics, Inc. (NASDAQ:CLDX) struggling like this. The shares have …
With the annual American Society of Clinical Oncology (ASCO) meeting round the corner, several companies are gearing up to present data at the conference. Last week, quite a few companies presented abstracts of data that will be …
so the stock should be in strong hands. Once it gets moving higher, you shouldn’t see a lot of sellers. This is the strategy that helped my subscribers earn a gain of 775% on NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) and more than 400% …
There has been a significant rally in the share price of Celldex (NASDAQ: CLDX) recently. The stock is still showing positive momentum due to strong data on its drug trials. This positive data makes the company an attractive target for …